\
&
Contact us
\
&
Contact us
Published on | 5 months ago
Programmes ERC ERCThe results of the 2024 European Research Council (ERC) Synergy Grant call (call deadline 15 November 2023) were published. Synergy grant projects consist of minimum two to maximum four Principal Investigators (PIs) and their teams that jointly address ambitious research problems that could not be addressed by the individual Principal Investigators and their teams working alone. In total 548 proposals were submitted for this call of which 57 projects with 201 PIs received a Synergy grant including one researcher based at a Flemish host institution:
Sara Bals (Universiteit Antwerpen) is involved in the project ‘CHIRAL-PRO - Handshake Complexes of Chiral Nanoparticles and Proteins’.
In the ERCEA news article the list of selected projects and several other examples of projects are highlighted.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space AI Continent Deployment: Best use of technologies
The Openverse project hosted last week a high-impact workshop, “National Initiatives and the European Partnership on Virtual Worlds,” aligning stakeholders around the European Commission’s Virtual Worlds strategy. The initiative, rooted in the July 2023 Communication on Web 4.0 and Virtual Worlds, aims to build sustainable, inclus... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
